186 related articles for article (PubMed ID: 8193463)
1. Aminohydroxypropylidene-biphosphonate in the treatment of bone lesions in a case of Gaucher's disease type 3.
Bembi B; Agosti E; Boehm P; Nassimbeni G; Zanatta M; Vidoni L
Acta Paediatr; 1994 Jan; 83(1):122-4. PubMed ID: 8193463
[TBL] [Abstract][Full Text] [Related]
2. Treatment of type 1 Gaucher's disease affecting bone with aminohydroxypropylidene bisphosphonate (pamidronate).
Ostlere L; Warner T; Meunier PJ; Hulme P; Hesp R; Watts RW; Reeve J
Q J Med; 1991 Jun; 79(290):503-15. PubMed ID: 1946931
[TBL] [Abstract][Full Text] [Related]
3. Aminohydroxy propylidene bisphosphonate (APD) treatment improves the clinical skeletal manifestations of Gaucher's disease.
Samuel R; Katz K; Papapoulos SE; Yosipovitch Z; Zaizov R; Liberman UA
Pediatrics; 1994 Sep; 94(3):385-9. PubMed ID: 8065868
[TBL] [Abstract][Full Text] [Related]
4. Gaucher's disease: a review.
Morales LE
Ann Pharmacother; 1996 Apr; 30(4):381-8. PubMed ID: 8729893
[TBL] [Abstract][Full Text] [Related]
5. Regression of bone lesions in Gaucher's disease during treatment with aminohydroxypropylidene bisphosphonate.
Harinck HI; Bijvoet OL; van der Meer JW; Jones B; Onvlee GJ
Lancet; 1984 Sep; 2(8401):513. PubMed ID: 6147561
[No Abstract] [Full Text] [Related]
6. [Bone manifestations of Gaucher's disease in Mexican patients].
Blass PJ
Acta Ortop Mex; 2010; 24(5):351-8. PubMed ID: 21246808
[TBL] [Abstract][Full Text] [Related]
7. [Gaucher disease: diagnosis and treatment].
Fumić K; Stavljenić-Rukavina A; Mrsić M; Potocki K
Acta Med Croatica; 2004; 58(5):353-8. PubMed ID: 15756799
[TBL] [Abstract][Full Text] [Related]
8. Alglucerase. A review of its therapeutic use in Gaucher's disease.
Whittington R; Goa KL
Drugs; 1992 Jul; 44(1):72-93. PubMed ID: 1379912
[TBL] [Abstract][Full Text] [Related]
9. Short-term effects of pamidronate in patients with Gaucher's disease and severe skeletal involvement.
Ciana G; Cuttini M; Bembi B
N Engl J Med; 1997 Sep; 337(10):712. PubMed ID: 9280823
[No Abstract] [Full Text] [Related]
10. Gaucher's disease in Lithuania: its diagnosis and treatment.
Kleinotienė G; Tylki-Szymanska A; Czartoryska B
Medicina (Kaunas); 2011; 47(7):405-11. PubMed ID: 22112991
[TBL] [Abstract][Full Text] [Related]
11. Biochemical markers of bone turnover as tools in the evaluation of skeletal involvement in patients with type 1 Gaucher disease.
Drugan C; Jebeleanu G; Grigorescu-Sido P; Caillaud C; Craciun AM
Blood Cells Mol Dis; 2002; 28(1):13-20. PubMed ID: 11814307
[TBL] [Abstract][Full Text] [Related]
12. Extraosseous manifestation of Gaucher's disease type I: MR and histological appearance.
Poll LW; Koch JA; vom Dahl S; Loxtermann E; Sarbia M; Niederau C; Häussinger D; Mödder U
Eur Radiol; 2000; 10(10):1660-3. PubMed ID: 11044944
[TBL] [Abstract][Full Text] [Related]
13. [Gaucher's disease--ocular manifestation and treatment].
Filipek E; Koraszewska-Matuszewska B
Klin Oczna; 2006; 108(7-9):357-60. PubMed ID: 17290842
[TBL] [Abstract][Full Text] [Related]
14. Management of bone disease in Gaucher disease type 1: clinical practice.
Giuffrida G; Cappellini MD; Carubbi F; Di Rocco M; Iolascon G
Adv Ther; 2014 Dec; 31(12):1197-212. PubMed ID: 25515322
[TBL] [Abstract][Full Text] [Related]
15. Improvement In Symptoms Of Gaucher's Disease By Enzyme Replacement Therapy.
Mazher W; Ali J; Abubakar S; Basar S; Murtaza G
J Ayub Med Coll Abbottabad; 2018; 30(3):479-481. PubMed ID: 30465391
[TBL] [Abstract][Full Text] [Related]
16. [Uveitis masquerade syndrome in Gaucher disease. Causal treatment by alglucerase substitution therapy].
Dann K; Althaus C; Kersten A; vom Dahl S; Sundmacher R
Klin Monbl Augenheilkd; 1998 Dec; 213(6):358-61. PubMed ID: 10048015
[TBL] [Abstract][Full Text] [Related]
17. Intravenous bisphosphonate treatment and pregnancy: its effects on mother and infant bone health.
Mastaglia SR; Watman NP; Oliveri B
Osteoporos Int; 2010 Nov; 21(11):1959-62. PubMed ID: 20535608
[TBL] [Abstract][Full Text] [Related]
18. [Persistence of pulmonary lesions in a 6-year-old boy with type I Gaucher's disease treated by alglucerase since the age of 20 months].
Versteegh C; Avni F; Cuvelier P; Ferster A
Arch Pediatr; 1998 Dec; 5(12):1341-3. PubMed ID: 9885741
[TBL] [Abstract][Full Text] [Related]
19. Gaucher's disease: clinical features and natural history.
Cox TM; Schofield JP
Baillieres Clin Haematol; 1997 Dec; 10(4):657-89. PubMed ID: 9497857
[TBL] [Abstract][Full Text] [Related]
20. Contribution of brain inflammation to neuronal cell death in neuronopathic forms of Gaucher's disease.
Vitner EB; Farfel-Becker T; Eilam R; Biton I; Futerman AH
Brain; 2012 Jun; 135(Pt 6):1724-35. PubMed ID: 22566609
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
